Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open label study to evaluate the colesevelam HCL for accelerated elimination of teriflunomide, and monitoring of teriflunomide concentration using dried blood spot assay.

Next Previous
Trial Profile

An open label study to evaluate the colesevelam HCL for accelerated elimination of teriflunomide, and monitoring of teriflunomide concentration using dried blood spot assay.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 02 Feb 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Colesevelam (Primary) ; Teriflunomide
  • Indications Multiple sclerosis
  • Focus Therapeutic Use

Most Recent Events

  • 25 Jan 2017 Results published in the Journal of Clinical Pharmacology.
  • 21 Aug 2015 New trial record
  • 23 Jun 2015 Results presented at the 1st Congress of the European Academy of Neurology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top